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Abstract
Rare respiratory diseases (RRDs) are a heterogeneous group of disorders
that collectively represent a significant health care burden. In recent
years, strong advocacy and policy initiatives have led to advances in the
implementation of research and clinical care for rare diseases. The
development of specialized centers and research networks has facilitated
support for affected individuals as well as emerging programs in basic,
translational, andclinical research. In selectedRRDs, subsequentgains in
knowledge have informed the development of targeted therapies and
effective diagnostic tests, but many gaps persist. There was therefore a
desire to identify the elements contributing to an effective translational
research program in RRDs. To this end, a workshop was convened
in October 2015 with a focus on the implementation of effective
transnational research networks and collaborations aimed at developing
novel diagnostic and therapeutic tools. Key elements included an
emphasis on molecular pathogenesis, the continuing engagement of
patient advocacy groups and policy makers, the effective use of
preclinicalmodels in the translational research pipeline, and the detailed
phenotyping of patient cohorts. During the course of the workshop,
current logistical and knowledge gapswere identified, andnew solutions
or opportunities were highlighted.
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Rare or orphan diseases are defined as those
with a prevalence of less than 1 in 2,000, or
less than 200,000 cases in the United States.
When combined, they affect approximately
5 to 8% of the population, but these
disorders have been underrepresented in
the spectrum of health care services
delivery, as well as in the distribution of
resources for clinical and translational
research. Rare respiratory diseases (RRDs)
make up an important subset (1, 2), and
respiratory manifestations have a
significant impact on patients’ quality of
life, function, and mortality. Although
prevalence estimates vary widely, RRDs
are estimated to affect up to 3 million
persons in each of Europe and the United
States (3). Recent reviews and statements
(3–5) have identified gaps in the
implementation of effective research and
care delivery for patients with RRDs. The
discovery and evaluation of biological
tools for clinical use (i.e., translational
research) were identified as priorities. To
accelerate advances in the field, there was a
perceived need to formalize the approach
to effective translational research
infrastructures and methodologies in
RRDs, using selected RRDs as illustrative
examples. The purpose of this document is
to summarize discussion from a workshop
convened in October 2015 at which the
optimization of translational research
in RRDs was addressed, in addition
to current gaps and emerging
opportunities.
Methods
An RRD workshop was held in Montreal,
Quebec, Canada, on October 22–23, 2015.
The goal was to build upon existing
knowledge based on RRD research and
provide consensus on its optimal
organization and required infrastructure.
The planning group and workshop were
chaired by A.S.K., B.J.P., and Q.H.
Workshop participants were chosen for
their leadership roles in existing RRD
research networks and programs, and they
included representatives of patient advisory
groups and local networks, patients with
RRDs, clinician scientists, respiratory
therapists, nurses, researchers, and trainees.
Speakers were responsible for reviewing
emerging infrastructures, methodologies,
and areas of need in facilitating
translational research in RRDs. Each
workshop speaker contributed to the
writing of this article. The workshop
consisted of individual sections that
covered five research-driven themes. All
planning committee members and
presenters completed a Declaration of
Potential Conflict of Interest Form prior to
the workshop.
Section 1: The Organization of
Translational Research
in RRDs
The goal of translational research is
to exploit knowledge gained from
experimental or clinical models to develop
new diagnostics or therapeutics for patients
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Figure 1. Optimizing translational research platforms for rare respiratory diseases (RRDs). Effective
translational research on RRDs requires an integrated infrastructure that interfaces with critical
stakeholders. Patient advisory groups and referral centers form a critical entry point and represent
end users in the research pipeline (blue). The development of patient cohorts and recruitment into
observational studies or clinical trials is facilitated by dedicated centers that participate in organized
networks (orange). Key personnel (i.e., clinician scientists, clinical research coordinator/nurse, core
experts in molecular pathophysiology) manage complex, multisystem chronic diseases, sample and
data collection and analysis, as well as communicate with stakeholders and network partners.
Understanding of disease pathogenesis is crucial, and the research exploits preclinical models,
access to biobanks and registries, detailed clinical and phenotypic analysis in observational studies,
and incorporation of diagnostic and prognostic biomarkers. Obstacles in RRD trial design include
small sample sizes, chronicity, and limited effects over time. Emerging techniques include adaptive
designs, N-of-1 and crossover trials, the incorporation of diagnostic or prognostic biomarkers, and
clinical surrogate markers (e.g., the use of baseline decline in lung function prior to the intervention).
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(6) (Figure 1). Traditional therapeutic
development pathways are focused on
screening-based technologies to identify
new compounds and biomarkers and to
target large populations for phase III
clinical trials and postmarketing analysis.
Although these populations are small for
RRDs, the genetic or molecular defect is
often known and can be exploited to define
accessible therapeutic targets. This also
permits the parallel development of
biomarkers that serve as strong surrogate
outcome variables in clinical trials. For
instance, studies in model organisms to
elucidate the role of the mechanistic target
of rapamycin (mTOR) in the control of cell
growth (7) complemented the interrogation
of patient-derived biopsy samples for
aberrant mTOR signaling and its role in the
pathogenesis of lymphangioleiomyomatosis
(LAM) (8). Within 10 years, a phase III
clinical trial demonstrated the efficacy of
the mTOR inhibitor rapamycin (sirolimus)
in improving lung function and quality of
life for patients with LAM (9, 10), and it
helped establish clinical guidelines for the
medical community (11, 12). In pulmonary
alveolar proteinosis, studies on granulocyte-
macrophage colony-stimulating factor
signaling in isolated macrophages informed
the characterization of granulocyte-
macrophage colony-stimulating factor
deficiency in patients and led to the
development of diagnostic bioassays and
replacement therapies (13). Similarly,
studies on the genetic and molecular bases
of cystic fibrosis (CF) have identified molecular
targets for cystic fibrosis transmembrane
conductance regulator (CFTR) corrector or
potentiator therapies (14, 15).
RRD advocates have implemented
innovative policy initiatives and research
infrastructures to address the shortfalls in
available clinical tools. One key step was the
incorporation of all rare diseases under
umbrella organizations that represent
common clinical and research needs. In
the United States, the National Institutes
of Health Office of Rare Diseases was
established in 1993, in part because of efforts
by the National Organization for Rare
Disorders advocacy group. The Rare
Diseases Clinical Research Network (251
institutions worldwide and .200 rare
diseases) was established to create
disease-specific consortia; cost-sharing
arrangements for research infrastructures;
uniform data acquisition protocols; and an
umbrella organization for disease registries,
cohort studies, and randomized controlled
trials. Additional missions include the
direct engagement of patients and their
advocates, as well as the training of new
investigators. As a platform, the network
facilitates clinical and translational research
by establishing standard operating
procedures for data collection, coordinating
patient recruitment for large-scale studies,
and providing a data management and
coordinating center that supports study
design and data analysis.
The Rare Lung Diseases Consortium
is a subset of the Rare Diseases Clinical
Research Network that collaborates with
patient advocacy groups and supports the
inclusion of those with no existing advocacy
vehicle. The National Center for Advancing
Translational Sciences was established to
support the preclinical and clinical development
of drugs and diagnostics for rare diseases.
Similar advocacy organizations operate globally,
including those represented at the workshop
(see Table E1 in the online supplement).
Moreover, a formalized, consortium-based
approach to translational research in rare
diseases of pediatric onset has been successfully
implemented (16). Therefore, rare disease
research networks, in collaboration with
patient advocacy groups and policy makers,
serve as critical drivers and coordinators of
clinical and translational research.
Section 2: Advances in Clinical
Infrastructure for Translational
Research in RRDs
Successful clinical and translational research
platforms for RRDs benefit from network-
based recruitment of patients into prospective
and longitudinal cohort studies that ideally
encompass the pediatric-to-adult spectrum.
The collection and analysis of granular
(i.e., detailed) datasets allows for precise
phenotyping, which supports research on
basic disease mechanisms and the design of
clinical trials by developing robust surrogate
physiological or molecular outcomes
(i.e., biomarkers). The elements of the
translational research backbone discussed are
described in the subsections below.
Registries and natural history studies
Registries are data collection systems suited
for tracking outcomes in chronic diseases
that can be accurately defined and rely on
voluntary provision of secondary patient
data from multiple centers to central
repositories. Estimates of disease prevalence,
practice patterns, and health care use
can be inferred. However, the accuracy,
homogeneity, and timeliness of clinical data
cannot be guaranteed, and coordination for
banking of biological samples is challenging.
Natural history studies can be designed
to collect a highly granular clinical and
biological dataset over time. The quality
and consistency of the data are optimized
by centralization of protocols, banking
repositories, and consistent measurement and
analytic techniques. Genetic and molecular
determinants can be tracked over time and
correlated with clinical outcomes. Given
the relative homogeneity of the patient
populations, the collection of multiple data
parameters over time can reduce bias and
permit inference from retrospective analyses.
For instance, a National Institutes of
Health–funded registry and natural history
study were initiated in parallel. Registry
data described the clinical spectrum of
LAM (17). The NHLBI LAM natural
history study was designed to frequently
assess the evolution of disease and included
the collection of biological samples that
could be linked to clinical data. As a result,
mTOR, along with multiple other putative
therapeutic targets, was validated as an
important disease modifier (18). Isolation
of circulating tumor cells revealed that the
abnormal cells in LAM exhibit metastatic
properties (19). A number of biomarkers
were identified in the blood (e.g., vascular
endothelial growth factor-D [VEGF-D]) (20)
and correlated with surrogate physiological or
radiological outcomes. Detailed clinical and
molecular phenotyping identified subsets of
patients with differences in prognosis (e.g.,
rate of decline in FEV1) or response to
treatment (e.g., VEGF-D), which can inform
the interpretation and design of translational
or clinical studies.
Longitudinal cohorts that encompass
the pediatric-to-adult spectrum
Because most rare diseases begin in
childhood, the identification of early
determinants of disease progression and
developmental trends in longitudinal
cohorts using adaptable study designs is
desirable. Potential challenges include their
long duration and expense, subject attrition,
and requirement for large sample sizes.
Attrition can be especially problematic
during the transition from pediatric to adult
care. However, these are often minimized
in RRD research by the availability of
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molecular testing and biomarkers, as well as
the involvement of patient advisory groups
in research networks. Illustrative successes
and gaps were discussed for infant
respiratory distress syndrome and
bronchopulmonary dysplasia (BPD), which
occur most commonly in preterm infants
and with effects spanning the pediatric-to-
adult continuum. Gaps include lack
of genetic and molecular markers of
disease progression and suboptimal
characterization of lung function over
time. Potential solutions include the
establishment of pediatric-to-adult
transition and RRD clinics that minimize
the loss to follow-up that occurs as patients
exit pediatric care models and facilitate
multidisciplinary translational research
studies. For instance, the maximum
potential FEV1, as defined by the peak FEV1
before decline begins (approximately age
24 yr), may differ among RRDs and could
serve as an important surrogate endpoint
for future decline or for assessing molecular
and genetic markers of disease progression.
In a cohort of 21-year-old patients with
premature birth and BPD, the median
maximum FEV1 was 80% of predicted
and was associated with greater airflow
obstruction and bronchial hyperreactivity
than in those subjects without BPD (21).
The detailed characterization of transition
cohorts would inform the development
of surrogate markers of disease and
the evaluation of novel therapeutic
modalities.
Primary ciliary dyskinesia (PCD) is
another RRD that begins in childhood and
leads to chronic upper and lower respiratory
infections caused by loss of ciliary function
and defective mucociliary clearance (22).
Little is known regarding the progression of
lung function abnormalities into adulthood,
and studies have thus far been limited by
suboptimal pediatric-to-adult transition
follow-up. The Genetic Disorders of
Mucociliary Clearance Consortium and the
PCD Foundation are currently focused
on prospective evaluation of disease
heterogeneity and genotype–phenotype
correlation throughout the pediatric-to-
adult spectrum (see section 4). Successes
include establishing nasal nitric oxide as an
effective screening test for PCD, evaluating
inhaled hyperosmolar agents as a potential
therapy, and identifying novel mutations in
ciliary structure/function genes (see section 4)
(23). The PCD Foundation has recently
sponsored clinical guidelines for diagnosis
and management (23), which promote
awareness in the community and referral
to tertiary clinical and translational research
centers.
Clinical trials
As controlled experiments, randomized
clinical trials can be leveraged to discover
and evaluate novel disease mechanisms and
biomarkers. The Multicenter International
Lymphangioleiomyomatosis Efficacy of
Sirolimus (MILES) trial investigators
evaluated the efficacy of sirolimus for the
prevention of lung function decline in
patients with LAM (10). VEGF-D levels
were elevated in patients with LAM but not
in those with other cystic lung diseases (24),
indicating its potential use as a diagnostic
biomarker. In the MILES trial, the authors
demonstrated a correlation between VEGF-
D levels and decline in lung function or
response to treatment (9). Researchers in
future trials may use elevated VEGF-D
levels as an enrollment criterion to both
target the most appropriate patient
population and optimize statistical power.
Key points discussed are summarized in
Figure 1.
Section 3: Preclinical Models
and Mechanisms of Disease
The use of preclinical cell-based and animal
models represents a crucial component in
the translational research pipeline. Although
they may not fully replicate human disease,
preclinical models can be employed to (1)
test mechanistic hypotheses generated
from clinical observations; (2) discover
new mechanisms of disease initiation,
susceptibility, or progression; (3) conduct
screens for novel therapies; and/or (4)
identify or validate biomarkers and test the
effectiveness of therapeutic approaches. In
addition, these models can incorporate
environmental factors (e.g., nutrition,
stress) that interact with genetic
determinants. Given the emphasis on
molecular pathogenesis in RRDs, these
models are well suited to complement RRD
translational research platforms. Selected




Translational investigators in CF, a protein-
trafficking disease, have conducted cell-based
drug screens using CFTR activity or
subcellular localization as endpoints to
identify potential “potentiator” or
“corrector” drugs, respectively (14).
Medium- to high-throughput ratiometric
and electrophysiological cell-based assays
(QPatch; Sophion Bioscience, Woburn,
MA) were used to screen for CFTR
correctors before validation of potential
leads in standard epithelial ion transport
assays. A primary airway cell biobank was
established (Trans Canadian Network
Initiative and McGill University Cystic
Fibrosis Translational Research Centre)
with seven distinct CF mutations
represented, permitting the validation
and testing of lead compounds and
derivatives in patient-derived cultures.
This platform was used for the preclinical
development of latonduine, a proteostasis
modulator and bone fide CFD508
corrector (25).
More broadly, systems biology and
personalized medicine approaches provide a
strong rationale for lead development and
subsequent clinical trials. Genome-wide
transcriptional profiling of CF cell lines with
known CFTR mutations can complement
chemical screens that both identify
mutation-specific expression profiles and
screen for drugs that may modulate these
responses.
Stem cell and tissue engineering
technologies can also be used to establish
preclinical models and represent the
developmental and genetic backgrounds of
the aberrant disease-causing cell. Induced
pluripotent stem cells can be engineered
from patients before undergoing lineage-
dependent differentiation to propagate cell
cultures. In one study, induced pluripotent
stem cell technology was used to re-create
macrophages originally derived from a
patient with hereditary pulmonary alveolar
proteinosis (26). Reduced surfactant
clearance in hereditary pulmonary alveolar
proteinosis macrophages could be corrected
by lentiviral expression of wild-type
CSF2RA, thereby complementing the
endogenous mutated form. This model can
be used for drug screening, mechanistic
studies, or transplant therapy (27).
Murine transgenic models for
diseases of known genetic etiology
Murine models can be used to explore
mechanisms of disease susceptibility arising
from known human genetic mutations.
Mutations in the HPS1 gene cause
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Hermansky-Pudlak syndrome, in which
affected individuals develop severe pulmonary
fibrosis. Although Hps-transgenic models
do not spontaneously develop disease, they
are more susceptible to injury-induced
(e.g., bleomycin) fibrosis via a mechanism
that requires epithelial cell apoptosis,
as well as the subsequent profibrotic
activation of alveolar macrophages
(28–31). Genetic mutations seen in
human subjects can be replicated
in mouse models to explore mechanisms
of disease and reveal additional cell-based
or molecular therapeutic targets.
Murine models for RRDs with no
unique molecular etiology
The absence of a defined disease-causing
genetic mutation and the inability to fully
reproduce pathological features of the
human disease in mice present significant
challenges. In idiopathic pulmonary fibrosis
(IPF), the initiating event is not known, and
murine models of fibrosis may use a variety
of artificial induction agents to reproduce
the pathophysiology. The routine use of
inbredmice reduces experimental variability
but does not address the genetic
heterogeneity in human cohorts. Often, the
timing or context of model initiation (e.g.,
age or sex of mice), interventions, or
measurement of endpoints is not applicable
to the clinical setting. Chronicity of the
phenotype may hinder the use of fully
representative experimental models because
of animal care and use ethical guidelines,
experimental complexity, or resource
limitations. In IPF, researchers in
translational studies have nonetheless
attempted to focus on mechanisms of
fibrosis and resulting loss of pulmonary
function. These include aging-related
susceptibility factors, aberrant epithelial cell
function, and factors leading to excessive
wound healing and lung remodeling (32).
Murine models have been refined
significantly by the use of repetitive
induction (e.g., bleomycin [33]) and
adenoviral gene transfer (e.g., adenoviral
vector expressing human transforming
growth factor-b [34]), as well as in vivo
lineage tracing and stem cell technologies
that permit the assessment of individual
cell types over time (35). Contemporary
murine studies incorporate chronicity,
factors that initiate or promote fibrosis,
interventional trial design, and clinically
relevant endpoints that render the
models translatable and amenable to
the development of diagnostic biomarkers
and therapeutics. As a result, translational
animal experiments can complement
successful large-scale human phase III
studies (36, 37). Key points discussed are
summarized in Table 1.
Section 4: Phenotyping and
Biomarker Development
RRDs often exhibit significant phenotypic
heterogeneity, which can be exploited to
better understand mechanisms of disease or
to design clinical studies that incorporate
the analysis of outcomes in population
subgroups. Modern high-throughput
technologies permit large-scale DNA
sequencing, which can link clinical
phenotypes to a defined molecular etiology.
Workshop participants discussed the
paradigms described below to illustrate
the utility of population phenotyping
in RRDs and how this informs the
development of well-defined surrogate
endpoints for the effective design of
clinical trials.
Phenotyping by respiratory function
The collection of granular physiological
data over time (section 2) is crucial for
understanding patient heterogeneity in
RRDs. Patients with LAM exhibit different
rates of decline in FEV1 and diffusing
capacity of the lung for carbon monoxide
over time, which correlates directly with
disease-related morbidity (38). These
surrogate endpoints can be exploited
to identify and characterize other
biomarkers of disease severity, as well as
to differentiate between responders and
nonresponders to therapy. The surrogate
endpoint approach can greatly reduce the
sample size in clinical trials. Importantly,
clinical trials in which changes in lung
function in the placebo or treatment
arms exhibit variability may yield
negative results even if many of the
patients respond to the intervention. In
one study of patients with Hermansky-
Pudlak syndrome, a salutary effect of
pirfenidone on lung function did not
achieve statistical significance; patient
selection by prior rate of decline in lung
function might have resulted in positive
results, and pirfenidone could have been
approved for this indication (39). Finally,
novel clinical trial designs (e.g., N-of-1,
crossover, adaptive) can complement the
use of surrogate physiological endpoints
in optimizing clinical and translational
protocols (40, 41).
Using biomarkers to identify disease
in presymptomatic patients
Another major challenge is to identify
patients at risk for developing clinically
significant disease so that prognostic and
therapeutic tools can be employed early
on. For instance, screening computed
Table 1. Preclinical models
Key Messages Current Challenges
d Preclinical cell-based and animal
models represent a critical component
of the translational pipeline in RRDs.
d The development of appropriate animal
models to study the effect of genetic
variation and/or environmental factors
on disease initiation or progression
d New technologies, improved study
design, and the incorporation of
chronicity permit the establishment of
preclinical models that enhance the
translational research effort even if they
do not precisely replicate the human
disease.
d The establishment of single-center or
networked translational research
platforms that incorporate patient care,
cohort development, and preclinical
investigations in the same pipeline to
support multidirectional interactions in
development of diagnostics and
therapeuticsd Induced pluripotent stem cells and in
vivo cell lineage tracking are promising
technologies to characterize
pathogenesis from early stages of
disease.
d The formulation of standard protocols
and endpoints for rapidly assessing the
regulatory requirements for entry into
human clinical trials
Definition of abbreviation: RRD = rare respiratory disease.
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tomographic (CT) scans or serum VEGF-D
levels in patients with tuberous sclerosis
(i.e., at risk for LAM) might permit the
identification and prognostication of
patients who subsequently develop LAM.
In a recent study with patients deemed at
risk for familial pneumonitis syndromes
on the basis of screening relatives of
affected patients, investigators identified
panels of clinical and molecular markers
that predict the onset of CT scan
abnormalities (42). These types of
phenotyping studies can greatly facilitate




RRD networks and patient-based advocacy
groups have contributed to the successful
collection of biological samples with linked
clinical data from natural history studies,
registries, and clinical trials. Samples can be
interrogated for genetic, transcriptomic, or
molecular biomarkers in an unbiased
fashion. In IPF, clinical outcomes were
associated with molecular “endotypes”
that reflect epithelial dysfunction and
senescence, innate immune responses, and
aberrant lung remodeling (43). Genetic,
transcriptomic, and proteomic patterns can
be used as quantitative surrogate endpoints
for stratification in clinical trials and as
clinical tools for prognostication
(i.e., personalized medicine). This was
illustrated in a study of N-acetylcysteine for
IPF: A single-nucleotide polymorphism
(rs3750920) in the TOLLIP gene predicted
improved clinical outcomes in patients with
IPF receiving N-acetylcysteine, whereas
clinical outcomes were worse in those with
the alternate allele (44, 45). In separate
studies, transcriptomic patterns in
peripheral blood mononuclear cells and
telomere length have been associated
with disease progression and/or acute
exacerbations (46, 47). The enrichment
of cohorts with potential responders to
treatment might be achieved using
biomarker panels that discriminate between
IPF and other forms of interstitial
pneumonitis (48) or those who are
predicted to exhibit biological responses
to therapy.
Phenotyping to discover rare variants
of common diseases
The detailed phenotyping of common
diseases can reveal rare variants that
potentially shed important insights into
disease pathogenesis. For instance, the
interrogation of DNA from families with
pulmonary fibrosis led to the identification
of candidate genes for therapeutics and
biomarker development (49). Detailed CT
image analysis of patients within chronic
obstructive pulmonary disease cohorts
(i.e., the Multi-Ethnic Study of
Atherosclerosis Lung Study) revealed that
specific airway segmental branching
variants were more common in patients
with chronic obstructive pulmonary disease
(B. M. Smith, oral communication, October
2015). These anatomical variants were in
turn associated with single-nucleotide
polymorphisms in a number of candidate
genes, which encode protein mediators
of lung development. Current studies
addressing mechanisms of disease in
respective mutant mice, as well as the
natural history of obstructive airway
disease in patients with these mutations,
might provide important insights into
factors that determine susceptibility to the
initiation or progression of common
airway diseases.
Genotype–phenotype correlation
Genotype–phenotype correlation is a
promising approach to understanding
mechanisms of disease and to classifying
patients within cohorts that are genetically
and phenotypically heterogeneous. A
translational approach was formalized by
the Genetic Disorders of Mucociliary
Clearance Consortium and the PCD
Foundation. Significant heterogeneity in the
clinical features of PCD can arise from age
of presentation, the presence and nature
of anatomical lateralization defects, the
severity of airway obstruction, upper airway
infections, infertility, and gastrointestinal
dysfunction (50, 51). Current diagnostic
modalities are focused on ciliary structure
and function, but they are often
cumbersome and subjective; fail to capture
the full spectrum of disease; and, especially
in young children, do not effectively
distinguish PCD from other syndromes
with similar clinical presentations (e.g., CF).
The complexity of ciliary composition
amplifies the number of potential causative
genes. Until 2008, identification of the first
eight genes associated with PCD relied
largely upon candidate gene-based
approaches using model organisms and
gene mapping by linkage analysis. Profiling
of the two initially discovered genes
(i.e., DNAI1, DNAH5) identified mutations
in nine exons that were used in the first
diagnostic test for PCD. Since 2009, the
pace of discovery has been accelerated by
next-generation sequencing technologies.
Currently, 35 genes are known to be
associated with PCD, accounting for
approximately two-thirds of all PCD cases.
Emerging insights into associations
between genotype and phenotype are
reviewed elsewhere (52). For example, there
is a strong association between genotype
and changes in ciliary structure and/or
function, and nasal nitric oxide levels are
usually low. DNAH11 mutations, however,
were observed in patients with normal
ciliary ultrastructure (53). Patients harboring
RSPH1 mutations exhibited a milder
pulmonary phenotype, and symptoms
became prevalent with age (54). The
identification of all disease-causing
mutations in PCD is now feasible using
current sequencing technologies, and
correlations with phenotype will permit the
optimization of counseling, prognostication,
and design of future clinical and
translational studies. Now commercially
available, next-generation sequencing
panels will also allow identification of
cases that require whole-exome
sequencing for novel gene discoveries.
Key points discussed are summarized in
Table 2.




Translational RRD research centers can
leverage growing international patient
cohorts, the power of patient advocacy, and
expertise in preclinical and clinical research
that addresses lung pathophysiology and
respiratory clinical outcomes. Workshop
organizers proposed that RRD translational
research platforms can investigate rare
neuromusculoskeletal diseases in which
respiratory manifestations account for
significant morbidity and mortality. As is
the case for other multisystem disorders
that significantly affect the lung (e.g., CF,
tuberous sclerosis complex), RRD
translational research programs could
develop clinical cohorts and preclinical
models, as discussed above, that
inform the development of diagnostics
and therapeutics for improving the
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quality of life and survival of these
patients.
Several examples of rare genetically
inherited and metabolic myopathies that
can present primarily with respiratory
manifestations in adults were discussed
(e.g., myotonic dystrophy, mitochondrial
myopathy, McArdle disease) (55). Pompe
disease, a glycogenosis caused by autosomal
recessive mutations in the acid a-glucosidase
(GAA) gene (56), was highlighted as
a rare neuromuscular disorder that
disproportionately affects the diaphragm.
Studies indicate a correlation between GAA
levels and the age of onset, as well as
progression of respiratory muscle
dysfunction. Exercise limitation, sleep-
disordered breathing, and aspiration
pneumonia are also associated with
increased morbidity and mortality.
Recombinant human GAA therapy slows
the loss of pulmonary function (57), but
diagnosis and treatment are often delayed.
In addition, detailed, long-term, respiration-
focused physiological and biological markers
of disease progression and response to
established or novel therapies are lacking.
These can potentially be developed in the
context of multinational collaborations,
special needs RRD clinics, and translational
research platforms.
Rare disorders of bone formation and
aberrant matrix production can also
result in chronic respiratory failure and
sleep-disordered breathing on the basis of
chest wall and/or parenchymal restriction.
Osteogenesis imperfecta (OI) is a genetically
inherited disease of bone fragility that
is usually caused by mutations in the
collagen type I genes (COL1A1, COL1A2),
with typical skeletal and extraskeletal
manifestations (58). Translational research
efforts in OI have been championed by
the Osteogenesis Imperfecta Foundation
and the Shriners Hospitals for Children
Network. Consistent genotype–phenotype
correlation and sensitivity of genetic
testing have defined a rich cohort in
which to study natural history and
potential therapies. Little is known
regarding changes in lung physiology and
gas exchange over time in patients with
OI, but respiratory dysfunction appears
to be a frequent cause of death (59, 60). A
crude analysis of 92 adults suggested a
correlation between scoliosis and reduced
lung function when corrected for arm
span (61). Based on spirometry, there
was evidence of obstructive airway
abnormalities in a significant proportion
of patients, even in the absence of
scoliosis, suggesting direct involvement
of the lung. The detailed characterization
of pulmonary function and gas exchange
over time in existing preclinical OI
models and genetically well-defined
clinical cohorts may provide important
insights into the evolution of pulmonary
disease in patients with OI or other
diseases of chest wall restriction.
Summary
Translational research in RRDs has led to an
explosion in novel diagnostic and therapeutic
approaches for previously neglected patients.
Optimal RRD translational research
programs require a coordinated and
multidisciplinary approach that relies on
an integrated infrastructure. Effective
translational research programs in RRDs are
managed by dedicated clinicians/scientists
and coordinators who facilitate
communications and collaboration with
transnational research networks, patient
advocacy groups, and policy makers.
Preclinical models of RRDs and patient
cohort phenotyping are critical in
determining the link between molecular
pathophysiology and disease
classification, respectively. The
development of screening assays and
surrogate physiological or biological
markers facilitates drug development
and the design of clinical trials, as well
as screening/diagnosis and disease
monitoring. Current gaps include the
detailed characterization of subjects
transitioning from pediatric to adult
care; the coordination of special needs
multidisciplinary clinics; regulatory
hurdles impeding interinstitutional
collaboration and drug or diagnostics
development; and novel clinical trial
designs that overcome chronicity,
heterogeneity, and effects of
cointerventions. Finally, it was proposed
that translational research platforms
in RRDs, which include multisystem
disorders that impact significantly upon
the lung, could incorporate subjects
with rare neuromusculoskeletal
diseases and potentially lead to the
conduct of research that ultimately has
a positive impact on their quality of life
and survival. n
Table 2. Phenotyping and biomarker development
Key Messages Current Challenges
d Simultaneous innovations in
physiological, imaging-based,
molecular, and genetic biomarker
discovery have greatly improved
patient care and facilitated the design
of clinical trials using surrogate
endpoints.
d Health disparities in the overall
population related to age, race, sex,
socioeconomic class, or geographical
location complicate effective patient
care and the recruitment of fully
representative cohorts. Health
disparities research might shed light on
mechanisms to account for phenotypic
and genetic variation in these
populations.
d A common infrastructure for pediatric
and adult RRDs could support
bidirectional preclinical and clinical
investigations, as well as mechanisms
to screen for early markers of disease
in otherwise asymptomatic patients.
d Despite the establishment of clinical
networks, subcontracting and
institutional review board agreements
represent significant hurdles in
conducting interinstitutional research.
The formulation of widely adopted
standard operating protocols, in
addition to the use of centralized,
multicenter processes, represents a
promising approach.d Detailed phenotypic analysis of
common disease cohorts might reveal
otherwise unknown rare diseases that
provide translatable genetic and
molecular insights.
Definition of abbreviation: RRD = rare respiratory disease.
AMERICAN THORACIC SOCIETY DOCUMENTS
American Thoracic Society Documents 1245
 
This official Workshop Report was prepared
by an ad hoc committee of the Assembly on
Respiratory Cell and Molecular Biology.
Members of the subcommittee are as follows:
ARNOLD S. KRISTOF, M.D. (Chair)
QUTAYBA HAMID, M.D., PH.D. (Co-Chair)
BASIL J. PETROF, M.D. (Co-Chair)
MARTIN KOLB, M.D., PH.D.
JENNIFER S. LANDRY, M.D.
ALEX MACKENZIE, M.D., Ph.D.
FRANCIS X. MCCORMACK, M.D.
JOEL MOSS, M.D., PH.D.
INGA J. MURAWSKI, PH.D.
FRANK RAUCH, M.D.
IVAN O. ROSAS, M.D.
ADAM J. SHAPIRO, M.D.
BENJAMIN M. SMITH, M.D.
DAVID Y. THOMAS, PH.D.
BRUCE C. TRAPNELL, M.D.
LISA R. YOUNG, M.D.
MAIMOONA A. ZARIWALA, PH.D.
Author disclosures: Q.H. served on an
advisory committee for Teva Pharmaceuticals;
received research support from Novartis and
GlaxoSmithKline. B.J.P. served as a speaker
and received research support from Genzyme.
M.K. served as a speaker, consultant, on an
advisory committee, on a data and safety
monitoring board, and received research
support from Boehringer Ingelheim,
F. Hoffman-La Roche/Roche/Intermune, and
GlaxoSmithKline; served as a consultant, on an
advisory committee, and received research
support from Gilead and Prometic; served as a
consultant and received research support from
Janssen; served on an advisory committee
AstraZeneca and Genoa; received research
support from Actelion and Sanofi. F.X.M.
served as a consultant for LAM Therapeutics;
served on an advisory committee and a data
and safety monitoring board for Takeda;
received research support from Novartis and
Pfizer; served on a clinical trial, Multicenter
International LAM Efficacy of Sirolimus (Miles);
holds an intellectual property on patent
8278060 for VEGF-D. F.R. served on an
advisory committee for Alexion and Ultragenyx;
received research support from Novartis. I.O.R.
served on an advisory committee for Patients
Like Me and Kadmon Pharmaceuticals; served
as a speaker for Genentech and Pri-Med;
holds an intellectual property on a patent for
biomarkers of IPF from Celgene; received
research support from Stomedix/Biogen,
Intermune, Gilead, and Bristol-Meyers Squibb.
A.J.S. received research support from Parion
Pharmaceuticals and Vertex Pharmaceuticals.
D.Y.T. served as company director and
employee for Traffic Therapeutics Inc. and
Triple R International Inc.; received
other payments from Amorchem Holdings
Inc.; received research support from
GlaxoSmithKline. B.C.T. received travel
support from Takeda; received research
support from aTyr Pharma. L.R.Y. has
intellectual property in royalties from
UpToDate and a patent for VEGF-D. M.A.Z.
received research support from Thermo-
Fisher Scientific and Life Technologies Corp.
A.S.K., J.S.L., A.M., J.M., I.J.M., and B.M.S.
reported no relationships with relevant
commercial interests.
Acknowledgment: J.M. was supported by
the Intramural Research Program, NIH, NHLBI.
The authors thank all the patients, Alpha-1
Canada (Jim Mundy), the Canadian
Organization for Rare Disorders (Wayne
Critchley), and the Regroupement québécois
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